Germany's 2024 Diabetes Summit: Heart, Kidney & Metabolic Breakthroughs

A study from Germany — specifically the 10th annual Cardiovascular Outcome Trial (CVOT) Summit hosted by the Forschergruppe Diabetes e. V. at Helmholtz Center Munich — has delivered one of the most comprehensive reviews of diabetes-related cardiovascular and kidney research published in recent years. Held virtually in December 2024, this international congress brought together endocrinologists, cardiologists, kidney specialists, and primary care physicians from around the world to evaluate the latest clinical trial data on medications that millions of Americans with diabetes already use or may soon be prescribed.

What Was Reviewed?

The summit examined results from six major clinical trials involving drugs that are either FDA-approved or under active review in the United States:

• Empagliflozin (Jardiance) — EMPACT-MI trial: Evaluated heart-protective effects following heart attack in people with diabetes.
• Semaglutide (Ozempic/Wegovy) — STEP-HFpEF-DM and FLOW trials: Showed meaningful benefits for people with heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD).
• Tirzepatide (Mounjaro/Zepbound) — SURMOUNT-OSA and SUMMIT trials: Demonstrated improvements in obstructive sleep apnea (OSA) and heart failure outcomes.
• Finerenone (Kerendia) — FINEARTS-HF trial: Showed kidney and heart benefits in patients with HFpEF.

Key Findings Explained in Plain English

These trials collectively show that today's newer diabetes and obesity medications do far more than lower blood sugar. They protect the heart, slow kidney decline, and even reduce dangerous breathing pauses during sleep. For US patients, this is especially significant: the American Diabetes Association (ADA) 2024 Standards of Care already recommend SGLT-2 inhibitors like empagliflozin and GLP-1 receptor agonists like semaglutide as first-line therapies for people with diabetes and existing heart or kidney disease — and this German summit reinforces why.

The congress also addressed Cardio-Kidney-Metabolic (CKM) Syndrome — a newly recognized cluster of conditions where heart disease, kidney disease, obesity, and diabetes feed into each other. This concept, also endorsed by the American Heart Association in 2023, helps explain why treating one condition often benefits others.

Additional Topics Relevant to US Patients

• Continuous Glucose Monitoring (CGM) and Automated Insulin Delivery (AID): The summit reviewed advances in diabetes technology that are rapidly expanding in the US market.
• Plastic Pollution and Heart Risk: Emerging research linking environmental plastics to cardiovascular disease risk — a growing public health concern in the US.
• Early Type 1 Diabetes Detection: Strategies to identify and potentially delay Type 1 diabetes before symptoms appear, relevant to families with genetic risk.
• Nutrition Under Incretin Therapies: Dietary guidance for patients on GLP-1 medications like Ozempic and Wegovy, addressing nutritional gaps that can occur with reduced appetite.

Why This Matters for US Patients

Germany's CVOT Summit is one of the most respected annual gatherings for diabetes-cardiovascular research globally. Because it synthesizes findings from multinational trials — many of which included thousands of American participants — its conclusions carry direct relevance for US patients and their doctors. If you have diabetes and heart failure, kidney disease, or sleep apnea, ask your doctor whether medications like empagliflozin, semaglutide, tirzepatide, or finerenone are appropriate for you. These drugs are not just about blood sugar control anymore — they may protect your heart and kidneys for years to come. The 11th CVOT Summit is scheduled for November 20–21, 2025.

Source: Schnell O, Almandoz J, Anderson J, et al. "CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes." Cardiovascular Diabetology, 2025. DOI: 10.1186/s12933-025-02700-0. PMID: 40316962.